AWH Stock Overview
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Aspira Women's Health Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.13 |
52 Week High | US$6.75 |
52 Week Low | US$0.86 |
Beta | 1.54 |
11 Month Change | -30.25% |
3 Month Change | -57.20% |
1 Year Change | -61.82% |
33 Year Change | -97.96% |
5 Year Change | -86.30% |
Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
AWH | US Medical Equipment | US Market | |
---|---|---|---|
7D | -2.6% | 1.6% | 3.6% |
1Y | -61.8% | 4.5% | 20.3% |
Return vs Industry: AWH underperformed the US Medical Equipment industry which returned 4.5% over the past year.
Return vs Market: AWH underperformed the US Market which returned 20.3% over the past year.
Price Volatility
AWH volatility | |
---|---|
AWH Average Weekly Movement | 20.1% |
Medical Equipment Industry Average Movement | 8.3% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AWH's share price has been volatile over the past 3 months.
Volatility Over Time: AWH's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 64 | Nicole Sandford | aspirawh.com |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
Aspira Women's Health Inc. Fundamentals Summary
AWH fundamental statistics | |
---|---|
Market cap | US$17.51m |
Earnings (TTM) | -US$15.95m |
Revenue (TTM) | US$8.92m |
2.0x
P/S Ratio-1.1x
P/E RatioIs AWH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AWH income statement (TTM) | |
---|---|
Revenue | US$8.92m |
Cost of Revenue | US$3.76m |
Gross Profit | US$5.16m |
Other Expenses | US$21.12m |
Earnings | -US$15.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.99 |
Gross Margin | 57.84% |
Net Profit Margin | -178.80% |
Debt/Equity Ratio | -47.1% |
How did AWH perform over the long term?
See historical performance and comparison